These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1324 related items for PubMed ID: 25886655

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 2: antipsychotics and traditional mood stabilizers.
    Pringsheim T, Hirsch L, Gardner D, Gorman DA.
    Can J Psychiatry; 2015 Feb; 60(2):52-61. PubMed ID: 25886656
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
    Dittmann RW, Schacht A, Helsberg K, Schneider-Fresenius C, Lehmann M, Lehmkuhl G, Wehmeier PM.
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder.
    Hazell P, Zhang S, Wolańczyk T, Barton J, Johnson M, Zuddas A, Danckaerts M, Ladikos A, Benn D, Yoran-Hegesh R, Zeiner P, Michelson D.
    Eur Child Adolesc Psychiatry; 2006 Mar; 15(2):105-10. PubMed ID: 16523251
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
    Hazell P, Becker K, Nikkanen EA, Trzepacz PT, Tanaka Y, Tabas L, D'Souza DN, Witcher J, Long A, Ponsler G, Dittmann RW.
    Atten Defic Hyperact Disord; 2009 Dec; 1(2):201-10. PubMed ID: 20234828
    [Abstract] [Full Text] [Related]

  • 15. Long-acting methylphenidate has an effect on aggressive behavior in children with attention-deficit/hyperactivity disorder.
    Sinzig J, Döpfner M, Lehmkuhl G, German Methylphenidate Study Group, Uebel H, Schmeck K, Poustka F, Gerber WD, Günter M, Knölker U, Gehrke M, Hässler F, Resch F, Brünger M, Ose C, Fischer R.
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):421-32. PubMed ID: 17822338
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME, Hazell P, Danckaerts M, Hoare P, Coghill DR, Wehmeier PM, Williams DW, Moore RJ, Levine L, Atomoxetine ADHD/ODD Study Group.
    Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 67.